Cancer

The purpose of this study is to determine the effectiveness of two different wellness programs for breast cancer survivors and their family members. One program is called Cancer Health Education, and the other is called CBCT (Cognitively-Based Compassion Training). Both programs will be conducted online through Zoom (a video-based conference system) from your tablet or computer. The CBCT program will be delivered to survivors and a family member together, or just to the survivor

Primary disease category: 
Secondary disease category(ies): 

Cancer misinformation (i.e., false, inaccurate or incomplete information) on social media will be examined with a special focus on adolescent and young adult cancer patients and their caregivers. Given the high use of social media by these cancer patients and their caregivers, cancer misinformation may influence their beliefs and attitudes in potentially serious ways. Making decisions based on misinformation could lead to poor health outcomes and decreased survival. 

Primary disease category: 
Secondary disease category(ies): 

UA botanical researchers are aiming to improve management options for women diagnosed with breast cancer by understanding the safety and potential benefits of over the counter supplements. As part of this effort, we are reaching out to women who have been diagnosed with breast cancer to find out more about the supplements that they may already be using. To participate, a short (5 minute) anonymous survey is available online (see link).

Primary disease category: 

Testing if radiation, hormone therapy, and docetaxel versus radiation and hormone therapy after prostectomy decreases cancer recurrence

Primary disease category: 

For patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL), treatment options have been limited and prognosis unfavorable. With the recent approval of BLINCYTO® (blinatumomab) in the US, it is important to understand its “real-world” utilization and to assess and understand its effectiveness and safety when administered in clinical practice. This

Primary disease category: 

The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in response to neoadjuvant sequential therapy of combination nab-paclitaxel and gemcitabine followed by stereotactic body radiotherapy (SBRT).

Primary disease category: 

This is a non-interventional, observational study. Multiple myeloma will be treated as per standard therapy and/or with medicinal product prescribed by the treating healthcare provider based upon his/her clinical judgment.

Primary disease category: 

Pages

Subscribe to RSS - Cancer